BioNetwork Partnering Summit
Privo CEO, Dr. Manijeh Goldberg, is invited to speak at the BioNetwork Partnering Summit.
Related Posts
09Sep
Privo Technologies, Inc. Awarded $2M Direct-to-Phase II Contract from the National Cancer Institute for PRV311 Treatment of Cervical Cancer
PEABODY, Mass., Sept. 9, 2022 /PRNewswire/ -- Privo Technologies, Inc. ("Privo", "the Company") announced today that it has been awarded a $2M Direct-to-Phase II... read more
12Nov
Privo Technologies receives $3M Bridge Award from the National Cancer Institute (NCI).
Privo Technologies (Privo) has been selected for the prestigious Phase IIB Bridge Award from the National Cancer Institute (NCI). The NCI SBIR... read more
07Dec
Privo Technologies, Inc. To Attend Bio Partnering at JPM January 10 to January 14, 2022
Peabody, MA-- Privo Technologies, Inc. (“Privo”), a clinical-stage biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer,... read more
01Apr
National Cancer Institute awards
Privo a $2.5M grant to optimize it lead product and prepare for its IND. read more
08Sep
Forbes Article “Going Beyond Target Or Mechanism Of Disease: Disruptive Innovation In Drug Delivery Systems”
Privo is excited to share the recent Forbes article titled, "Going Beyond Target Or Mechanism Of Disease: Disruptive Innovation... read more
07Sep
FDA Grants $2 million award to Privo Technologies to expedite its clinical trial
Privo Technologies has been awarded ~$2 million in funding from the FDA through its Office of Orphan Product Development (OOPD)... read more
17Apr
Privo Technology’s CEO, Manijeh Goldberg, speaks at IDEASTREAM, MIT Deshpande Center Symposium.
Watch Dr. Goldberg's presentation below regarding localized treatment of cancers in a more safe and effective way and the positive... read more
26Jan
Privo Technologies Successfully Completes Phase 1/2 Study of PRV211 Intraoperative Chemotherapy for Head and Neck Cancer Patients Novel Surgical Innovation Demonstrates Excellent Safety Profile with Potential to Reduce Tumor Recurrence
BOSTON, January 23, 2026 – Privo Technologies, Inc. today announced the successful completion of its Phase 1/2 clinical evaluation of... read more
27Aug
Privo Technologies, Inc. Announces Publication in Nature Communications
PEABODY, Mass., Aug. 24, 2022 /PRNewswire/ -- Privo Technologies, Inc. ("Privo"), a phase 3 clinical stage biopharmaceutical company that has designed... read more
24Oct
Privo Technologies begins FDA Approved Clinical Trials
BOSTON, Oct. 24, 2018 /PRNewswire/ -- Privo Technologies was granted the green light from the FDA and several hospitals this summer to... read more
- © UX Strategy & Digital Branding
